CrkL Antikörper (AA 286-303)

Produktnummer ABIN3029484

Produktdetails anti-CrkL Antikörper

Target: CrkL (CRKL) (V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like (CRKL))

Bindungsspezifität: AA 286-303

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CrkL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: Antigen affinity

Immunogen: Amino acids 286-303 (FPFTHVKIFDPQNPDENE-human) were used as the immunogen for this CrkL antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: The stated application concentrations are suggested starting amounts. Titration of the CrkL antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: -20 °C

Informationen zur Lagerung: After reconstitution, the CrkL antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Details zu CrkL

Target: CrkL (CRKL) (V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like (CRKL))

Andere Bezeichnung: CrkL (CRKL Produkte)

Synonyme: CRKL antikoerper, wu:fa55g05 antikoerper, wu:fj60e01 antikoerper, zgc:63469 antikoerper, 1110025F07Rik antikoerper, AA589403 antikoerper, AI325100 antikoerper, Crkol antikoerper, CRK like proto-oncogene, adaptor protein antikoerper, v-crk avian sarcoma virus CT10 oncogene homolog-like antikoerper, CRKL antikoerper, crkl antikoerper, Crkl antikoerper

Hintergrund: V-Crk sarcoma virus CT10 oncogene homolog(avian)-like), also called CrkL, encodes a 303-amino acid polypeptide with a predicted molecular mass of ~36 kD. While CrkL is not the human homolog of CRK, it is similar to protein-tyrosine kinases with SH2 and SH3 (src homology) domains. By fluorescence in situ hybridization,the gene is localized to chromosome 22q11, centromeric of the chronic myelogenous leukemia breakpoint region. Senechal et al.(1996)showed that CRKL becomes phosphorylated when overexpressed, activates Ras-dependent and JNK pathways, and transforms fibroblasts. The authors also found CrkL to be a substrate for the BCR-ABL tyrosine kinase, leading them to conclude that it is a tyrosine kinase and an oncogene. CrkLwas required for normal cellular responses to Fgf8, including survival and migration, Erk activation, and target gene expression.

UniProt: P46109

Pathways: Interferon-gamma Pathway, Neurotrophin Signalübertragung, Signaling of Hepatocyte Growth Factor Receptor